Wilson Horne Immunotherapy Centre and Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle-Upon-Tyne NE2 4HH, UK.
Arthritis Res Ther. 2009;11(3):225. doi: 10.1186/ar2594. Epub 2009 May 19.
There has been a therapeutic revolution in rheumatology over the past 15 years, characterised by a move away from oral immuno-suppressive drugs toward parenteral targeted biological therapies. The potency and relative safety of the newer agents has facilitated a more aggressive approach to treatment, with many more patients achieving disease remission. There is even a prevailing sense that disease 'cure' may be a realistic goal in the future. These developments were underpinned by an earlier revolution in molecular biology and protein engineering as well as key advances in our understanding of rheumatoid arthritis pathogenesis. This review will focus on antibody engineering as the key driver behind our current and developing range of antirheumatic treatments.
在过去的 15 年里，风湿病学领域发生了一场治疗革命，其特点是从口服免疫抑制剂转向靶向生物制剂。新型药物的效力和相对安全性促进了更积极的治疗方法，使更多的患者达到疾病缓解。甚至有一种普遍的感觉，即疾病“治愈”可能是未来的一个现实目标。这些发展的基础是分子生物学和蛋白质工程的早期革命，以及对类风湿关节炎发病机制的关键认识的进步。这篇综述将重点介绍抗体工程，因为它是我们当前和正在开发的一系列抗风湿治疗的关键驱动因素。
